Feedback plc announced a collaboration agreement with Vertex In Healthcare to combine key technologies and resell each other's products with a view to driving commercial opportunities in multiple markets. The Agreement enables the companies to work together and outlines the key terms which will form the basis of definitive commercial agreements for multiple collaborations. Vertex is the UK registered reseller of the MedDream medical image viewer, an advanced diagnostics web viewer manufactured by UAB Softneta, which has existing regulatory approval (FDA Cleared and CE Marked) in a number of territories including the USA, Middle East and Europe.

The Agreement will enable Feedback to incorporate the MedDream viewer into Bleepa, enabling Bleepa to be sold directly to Radiologists for primary diagnostic reporting services, strengthening the Company's teleradiology offering and expanding the reach of the product to new territories such as the USA. Embedding a viewer with existing regulatory approval in multiple international territories will enable the combined Bleepa/MedDream product to meet the regulatory requirements to be sold directly into these markets. Although the Company's primary international focus remains on its growing opportunity in India, this collaboration gives the Company the potential to expand into a number of key international territories as opportunities present themselves, most notably in the USA and Middle East.

The Agreement will position Feedback and Vertex to resell each other's products in multiple territories, allowing both entities to expand more rapidly and cost effectively into regions where the other has an existing footprint. Bleepa offers considerable value and product differentiation to Vertex's existing solutions in their current markets and will enable them to grow market share across multiple customer segments. As part of the Agreement, Vertex will licence the database capabilities of Feedback's legacy picture archiving communication system Cadran PACS, now with the MedDream Viewer, which will allow it to build a PACS proposition that will initially be sold in South Africa and other international markets including the UK, where it sells PACS.

This is another example of the Company's strategy to generate Licensing royalties from its legacy products. The Agreement covers a number of confidential commercial terms depending on the specific collaborative arrangement. Although no minimum targets are required, both companies are motivated to achieve high levels of commercialisation as a result of this Agreement.